DOCSLIB.ORG

PHYSICIAN and OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (Rvus) by CPT/HCPCS CODE

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PHYSICIAN and OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (Rvus) by CPT/HCPCS CODE TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE PAGE 1 of 135 Non- Facility CPT/ Conversion Status/ Work Facility Total Practice Charge HCPCS Modifier 1 CPT/HCPCS Code Description Factor/GAAF Usage Expense Practice Expense Expense Methodology 3 Code Category Indicator 2 RVUs Expense RVUs RVUs RVUs 01996 DAILY HOSP MGMT EDRL/SARACH CONT DRUG ADMN Anesthesia 2.62 Anesthesia 10021 FINE NEEDLE ASPIRATION W/O IMAGING GUIDANCE Surgery 1.27 0.55 2.78 RBRVS 10022 FINE NEEDLE ASPIRATION WITH IMAGING GUIDANCE Surgery 1.27 0.48 2.60 RBRVS 10030 IMAGE-GUIDED CATHETER FLUID COLLECTION DRAINAGE Surgery 3.00 1.17 18.76 RBRVS 10035 PERQ SFT TISS LOC DEVICE PLMT 1ST LES W/GDNCE Surgery 1.70 0.63 13.31 RBRVS 10036 PERQ SFT TISS LOC DEVICE PLMT ADD LES W/GDNCE Surgery 0.85 0.32 12.25 RBRVS 10040 ACNE SURGERY Surgery 1.21 1.14 1.50 RBRVS 10060 INCISION & DRAINAGE ABSCESS SIMPLE/SINGLE Surgery 1.22 1.42 1.97 RBRVS 10061 INCISION & DRAINAGE ABSCESS COMPLICATED/MULTIPLE Surgery 2.45 2.38 3.10 RBRVS 10080 INCISION & DRAINAGE PILONIDAL CYST SIMPLE Surgery 1.22 1.55 3.68 RBRVS 10081 INCISION & DRAINAGE PILONIDAL CYST COMPLICATED Surgery 2.50 2.01 4.76 RBRVS 10120 INCISION & REMOVAL FOREIGN BODY SUBQ TISS SIMPLE Surgery 1.22 1.59 2.95 RBRVS 10121 INCISION & REMOVAL FOREIGN BODY SUBQ TISS COMPL Surgery 2.74 2.17 4.61 RBRVS 10140 I&D HEMATOMA SEROMA/FLUID COLLECTION Surgery 1.58 1.61 2.85 RBRVS 10160 PUNCTURE ASPIRATION ABSCESS HEMATOMA BULLA/CYST Surgery 1.25 1.33 2.28 RBRVS 10180 INCISION & DRAINAGE COMPLEX PO WOUND INFECTION Surgery 2.30 2.33 4.19 RBRVS 11000 DBRDMT EXTENSV ECZEMA/INFECT SKN UP 10% BDY SURF Surgery 0.60 0.17 0.89 RBRVS 11001 DBRDMT EXTNSVE ECZEMA/INFECT SKN EA 10% BDY SURF Surgery 0.30 0.08 0.27 RBRVS 11004 DBRDMT SKN SUBQ T/M/F NECRO INFCTJ GENT&PR Surgery 10.80 3.91 3.91 RBRVS 11005 DBRDMT SKN SUBQ T/M/F NECRO INFCTJ ABDL WALL Surgery 14.24 5.21 5.21 RBRVS 11006 DBRDMT SKN SUBQ T/M/F NECRO INFCTJ GENT/ABDL Surgery 13.10 4.68 4.68 RBRVS 11008 REMOVAL PROSTHETIC MATRL ABDL WALL FOR INFECTION Surgery 5.00 1.83 1.83 RBRVS 11010 DBRDMT W/RMVL FM FX&/DISLC SKIN&SUBQ TISSUS Surgery 4.19 3.11 9.01 RBRVS 11011 DBRDMT W/RMVL FM FX&/DISLC SKN SUBQ T/M/F MUSC Surgery 4.94 2.68 9.10 RBRVS 11012 DBRDMT FX&/DISLC SUBQ T/M/F BONE Surgery 6.87 3.99 11.93 RBRVS 11042 DEBRIDEMENT SUBCUTANEOUS TISSUE 20 SQ CM/< Surgery 1.01 0.64 2.18 RBRVS 11043 DEBRIDEMENT MUSCLE & FASCIA 20 SQ CM/< Surgery 2.70 1.37 3.38 RBRVS 11044 DEBRIDEMENT BONE MUSCLE &/FASCIA 20 SQ CM/< Surgery 4.10 1.91 4.19 RBRVS 11045 DBRDMT SUBCUTANEOUS TISSUE EA ADDL 20 SQ CM Surgery 0.50 0.18 0.60 RBRVS 11046 DEBRIDEMENT MUSCLE &/FASCIA EA ADDL 20 SQ CM Surgery 1.03 0.40 0.87 RBRVS 11047 DEBRIDEMENT BONE EACH ADDITIONAL 20 SQ CM Surgery 1.80 0.72 1.39 RBRVS 11055 PARING/CUTTING BENIGN HYPERKERATOTIC LESION 1 Surgery 0.35 0.09 0.98 RBRVS 11056 PARING/CUTTING BENIGN HYPERKERATOTIC LESION 2-4 Surgery 0.50 0.12 1.12 RBRVS 11057 PARING/CUTTING BENIGN HYPERKERATOTIC LESION >4 Surgery 0.65 0.16 1.16 RBRVS 11100 BX SKIN SUBCUTANEOUS&/MUCOUS MEMBRANE 1 LESION Surgery 0.81 0.48 2.01 RBRVS 11101 BIOPSY SKIN SUBQ&/MUCOUS MEMBRANE EA ADDL LESN Surgery 0.41 0.25 0.46 RBRVS 11200 REMOVAL SKN TAGS MLT FIBRQ TAGS ANY AREA UPW/15 Surgery 0.82 1.17 1.57 RBRVS 11201 REMOVAL SK TGS MLT FIBRQ TAGS ANY AREA EA 10 Surgery 0.29 0.15 0.21 RBRVS 11300 SHAVING SKIN LESION 1 TRUNK/ARM/LEG DIAM 0.5CM/< Surgery 0.60 0.33 2.07 RBRVS 11301 SHVG SKIN LESION 1 TRUNK/ARM/LEG DIAM 0.6-1.0 CM Surgery 0.90 0.52 2.37 RBRVS 11302 SHVG SKN LESION 1 TRUNK/ARM/LEG DIAM 1.1-2.0 CM Surgery 1.05 0.61 2.79 RBRVS 11303 SHVG SKIN LESION 1 TRUNK/ARM/LEG DIAM >2.0 CM Surgery 1.25 0.71 2.98 RBRVS 11305 SHAVING SKIN LESION 1 S/N/H/F/G DIAM 0.5 CM/< Surgery 0.80 0.25 1.92 RBRVS 11306 SHAVING SKIN LESION 1 S/N/H/F/G DIAM 0.6-1.0 CM Surgery 0.96 0.42 2.37 RBRVS 11307 SHAVING SKIN LESION 1 S/N/H/F/G DIAM 1.1-2.0 CM Surgery 1.20 0.56 2.71 RBRVS 11308 SHAVING SKIN LESION 1 S/N/H/F/G DIAM >2.0 CM Surgery 1.46 0.51 2.66 RBRVS 11310 SHAVING SKIN LESION 1 F/E/E/N/L/M DIAM 0.5 CM/< Surgery 0.80 0.45 2.30 RBRVS 11311 SHVG SKIN LESION 1 F/E/E/N/L/M DIAM 0.6-1.0 CM Surgery 1.10 0.64 1.90 RBRVS 11312 SHVG SKIN LESION 1 F/E/E/N/L/M DIAM 1.1-2.0 CM Surgery 1.30 0.76 3.05 RBRVS 11313 SHAVING SKIN LESION 1 F/E/E/N/L/M DIAM >2.0 CM Surgery 1.68 0.96 3.32 RBRVS 11400 EXC B9 LESION MRGN XCP SK TG T/A/L 0.5 CM/< Surgery 0.90 1.27 2.49 RBRVS 11401 EXC B9 LESION MRGN XCP SK TG T/A/L 0.6-1.0 CM Surgery 1.28 1.50 2.75 RBRVS 11402 EXC B9 LESION MRGN XCP SK TG T/A/L 1.1-2.0 CM Surgery 1.45 1.59 3.01 RBRVS 11403 EXC B9 LESION MRGN XCP SK TG T/A/L 2.1-3.0 CM/< Surgery 1.84 2.07 3.27 RBRVS 11404 EXC B9 LESION MRGN XCP SK TG T/A/L 3.1-4.0 CM Surgery 2.11 2.16 3.66 RBRVS 11406 EXC B9 LESION MRGN XCP SK TG T/A/L >4.0 CM Surgery 3.52 2.85 4.66 RBRVS 11420 EXC B9 LESION MRGN XCP SK TG S/N/H/F/G 0.5 CM/< Surgery 1.03 1.18 2.32 RBRVS 11421 EXC B9 LESION MRGN XCP SK TG S/N/H/F/G 0.6-1.0CM Surgery 1.47 1.48 2.78 RBRVS 11422 EXC B9 LESION MRGN XCP SK TG S/N/H/F/G 1.1-2.0CM Surgery 1.68 1.95 3.04 RBRVS 11423 EXC B9 LESION MRGN XCP SK TG S/N/H/F/G 2.1-3.0CM Surgery 2.06 2.13 3.34 RBRVS 11424 EXC B9 LESION MRGN XCP SK TG S/N/H/F/G 3.1-4.0CM Surgery 2.48 2.27 3.72 RBRVS 11426 EXC B9 LESION MRGN XCP SK TG S/N/H/F/G > 4.0CM Surgery 4.09 3.05 4.62 RBRVS 11440 EXC B9 LESION MRGN XCP SK TG F/E/E/N/L/M 0.5CM/< Surgery 1.05 1.76 2.63 RBRVS 11441 EXC B9 LES MRGN XCP SK TG F/E/E/N/L/M 0.6-1.0CM Surgery 1.53 2.01 3.01 RBRVS 11442 EXC B9 LES MRGN XCP SK TG F/E/E/N/L/M 1.1-2.0CM Surgery 1.77 2.12 3.27 RBRVS 11443 EXC B9 LES MRGN XCP SK TG F/E/E/N/L/M 2.1-3.0CM Surgery 2.34 2.40 3.63 RBRVS 11444 EXC B9 LES MRGN XCP SK TG F/E/E/N/L/M 3.1-4.0CM Surgery 3.19 2.82 4.27 RBRVS 11446 EXC B9 LESION MRGN XCP SK TG F/E/E/N/L/M > 4.0CM Surgery 4.80 3.74 5.51 RBRVS 11450 EXCISION HIDRADENITIS AXILLARY SMPL/INTRM RPR Surgery 3.22 3.31 6.94 RBRVS 11451 EXCISION HIDRADENITIS AXILLARY COMPLEX REPAIR Surgery 4.43 3.91 8.37 RBRVS 11462 EXCISION HIDRADENITIS INGUINAL SMPL/INTRM RPR Surgery 3.00 3.24 6.88 RBRVS 11463 EXCISION HIDRADENITIS INGUINAL COMPLEX REPAIR Surgery 4.43 4.00 8.65 RBRVS 11470 EXCISION H/P/P/U SIMPLE/INTERMEDIATE REPAIR Surgery 3.74 3.52 7.15 RBRVS 11471 EXCISION H/P/P/U COMPLEX REPAIR Surgery 4.89 4.12 8.61 RBRVS 11600 EXCISION MAL LESION TRUNK/ARM/LEG 0.5 CM/< Surgery 1.63 1.56 3.57 RBRVS NOTE: CPT Codes and descriptions only are copyright 2015 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. 1, 2, 3 - See end of the table for notes regarding these fields. TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE PAGE 2 of 135 Non- Facility CPT/ Conversion Status/ Work Facility Total Practice Charge HCPCS Modifier 1 CPT/HCPCS Code Description Factor/GAAF Usage Expense Practice Expense Expense Methodology 3 Code Category Indicator 2 RVUs Expense RVUs RVUs RVUs 11601 EXCISION MAL LESION TRUNK/ARM/LEG 0.6-1.0 CM Surgery 2.07 1.90 4.09 RBRVS 11602 EXCISION MAL LESION TRUNK/ARM/LEG 1.1-2.0 CM Surgery 2.27 2.09 4.40 RBRVS 11603 EXCISION MAL LESION TRUNK/ARM/LEG 2.1-3.0 CM/< Surgery 2.82 2.37 4.76 RBRVS 11604 EXCISION MAL LESION TRUNK/ARM/LEG 3.1-4.0 CM Surgery 3.17 2.51 5.23 RBRVS 11606 EXCISION MALIGNANT LESION TRUNK/ARM/LEG > 4.0 CM Surgery 5.02 3.28 6.87 RBRVS 11620 EXCISION MALIGNANT LESION S/N/H/F/G 0.5 CM/< Surgery 1.64 1.58 3.61 RBRVS 11621 EXCISION MALIGNANT LESION S/N/H/F/G 0.6-1.0 CM Surgery 2.08 1.92 4.11 RBRVS 11622 EXCISION MALIGNANT LESION S/N/H/F/G 1.1-2.0 CM Surgery 2.41 2.16 4.48 RBRVS 11623 EXCISION MALIGNANT LESION S/N/H/F/G 2.1-3.0 CM/< Surgery 3.11 2.51 4.92 RBRVS 11624 EXCISION MALIGNANT LESION S/N/H/F/G 3.1-4.0 CM Surgery 3.62 2.70 5.39 RBRVS 11626 EXCISION MALIGNANT LESION S/N/H/F/G >4.0 CM Surgery 4.61 3.07 6.17 RBRVS 11640 EXCISION MALIGNANT LESION F/E/E/N/L 0.5 CM/< Surgery 1.67 1.67 3.74 RBRVS 11641 EXCISION MALIGNANT LESION F/E/E/N/L 0.6-1.0 CM Surgery 2.17 1.99 4.23 RBRVS 11642 EXCISION MALIGNANT LESION F/E/E/N/L 1.1-2.0 CM Surgery 2.62 2.28 4.66 RBRVS 11643 EXCISION MALIGNANT LESION F/E/E/N/L 2.1-3.0 CM Surgery 3.42 2.68 5.11 RBRVS 11644 EXCISION MALIGNANT LESION F/E/E/N/L 3.1-4.0 CM Surgery 4.34 3.15 6.15 RBRVS 11646 EXCISION MALIGNANT LESION F/E/E/N/L >4.0 CM Surgery 6.26 4.09 7.35 RBRVS 11719 TRIMMING NONDYSTROPHIC NAILS ANY NUMBER Surgery 0.17 0.04 0.21 RBRVS 11720 DEBRIDEMENT NAIL ANY METHOD 1-5 Surgery 0.32 0.08 0.57 RBRVS 11721 DEBRIDEMENT NAIL ANY METHOD 6/> Surgery 0.54 0.13 0.69 RBRVS 11730 AVULSION NAIL PLATE PARTIAL/COMPLETE SIMPLE 1 Surgery 1.10 0.27 1.62 RBRVS 11732 AVULSION NAIL PLATE PARTIAL/COMP SIMPLE EA ADDL Surgery 0.44 0.11 0.54 RBRVS 11740 EVACUATION SUBUNGUAL HEMATOMA Surgery 0.37 0.53 1.00 RBRVS 11750 EXCISION NAIL MATRIX PERMANENT REMOVAL Surgery 2.50 2.26 3.62 RBRVS 11752 EXC NAIL MATRIX PRM RMVL W/AMP TUFT DSTL PHALANX Surgery 3.63 3.45 5.14 RBRVS 11755 BIOPSY NAIL UNIT SEPARATE PROCEDURE Surgery 1.31 0.81 2.36 RBRVS 11760 REPAIR NAIL BED Surgery 1.63 1.91 4.62 RBRVS 11762 RECONSTRUCTION NAIL BED W/GRAFT Surgery 2.94 2.08 4.77 RBRVS 11765 WEDGE EXCISION SKIN NAIL FOLD Surgery 1.22 1.37 3.42 RBRVS 11770 EXCISION PILONIDAL CYST/SINUS SIMPLE Surgery 2.66 2.09 4.63 RBRVS 11771 EXCISION PILONIDAL CYST/SINUS EXTENSIVE Surgery 6.09 5.00 8.86 RBRVS 11772 EXCISION PILONIDAL CYST/SINUS COMPLICATED Surgery 7.35 7.58 10.86 RBRVS 11900 INJECTION INTRALESIONAL UP TO & INCLUD 7 LESIONS Surgery 0.52 0.31 0.98 RBRVS 11901 INJECTION INTRALESIONAL >7 LESIONS Surgery 0.80 0.48 1.07 RBRVS 11920 TATTOOING INCL MICROPIGMENTATION 6.0 CM/< Surgery
Load more

Recommended publications
  • Surgical Treatment of Snoring and Obstructive Sleep Apnea Syndrome
    Medical Policy Surgical Treatment of Snoring and Obstructive Sleep Apnea Syndrome Table of Contents Policy: Commercial Coding Information Information Pertaining to All Policies Policy: Medicare Description References Authorization Information Policy History Policy Number: 130 BCBSA Reference Number: 7.01.101 Related Policies None Policy Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members Uvulopalatopharyngoplasty (UPPP) may be MEDICALLY NECESSARY for the treatment of clinically significant obstructive sleep apnea syndrome (OSAS) in appropriately selected adult patients who have failed an adequate trial of continuous positive airway pressure (CPAP) or failed an adequate trial of an oral appliance (OA). Clinically significant OSA is defined as those patients who have: Apnea/hypopnea Index (AHI) or Respiratory Disturbance Index (RDI) 15 or more events per hour, or AHI or RDI 5 or more events and 14 or less events per hour with documented symptoms of excessive daytime sleepiness, impaired cognition, mood disorders or insomnia, or documented hypertension, ischemic heart disease, or history of stroke. Hyoid suspension, surgical modification of the tongue, and/or maxillofacial surgery, including mandibular- maxillary advancement (MMA), may be MEDICALLY NECESSARY in appropriately selected adult patients with clinically significant OSA and objective documentation of hypopharyngeal obstruction who have failed an adequate trial of continuous positive airway pressure (CPAP) or failed an adequate trial of an oral appliance (OA). Clinically significant OSA is defined as those patients who have: AHI or RDI 15 or more events per hour, or AHI or RDI 5 or more events and 14 or less events per hour with documented symptoms of excessive daytime sleepiness, impaired cognition, mood disorders or insomnia, or documented hypertension, ischemic heart disease, or history of stroke.
    [Show full text]
  • Chapter 28 *Lecture Powepoint
    Chapter 28 *Lecture PowePoint The Female Reproductive System *See separate FlexArt PowerPoint slides for all figures and tables preinserted into PowerPoint without notes. Copyright © The McGraw-Hill Companies, Inc. Permission required for reproduction or display. Introduction • The female reproductive system is more complex than the male system because it serves more purposes – Produces and delivers gametes – Provides nutrition and safe harbor for fetal development – Gives birth – Nourishes infant • Female system is more cyclic, and the hormones are secreted in a more complex sequence than the relatively steady secretion in the male 28-2 Sexual Differentiation • The two sexes indistinguishable for first 8 to 10 weeks of development • Female reproductive tract develops from the paramesonephric ducts – Not because of the positive action of any hormone – Because of the absence of testosterone and müllerian-inhibiting factor (MIF) 28-3 Reproductive Anatomy • Expected Learning Outcomes – Describe the structure of the ovary – Trace the female reproductive tract and describe the gross anatomy and histology of each organ – Identify the ligaments that support the female reproductive organs – Describe the blood supply to the female reproductive tract – Identify the external genitalia of the female – Describe the structure of the nonlactating breast 28-4 Sexual Differentiation • Without testosterone: – Causes mesonephric ducts to degenerate – Genital tubercle becomes the glans clitoris – Urogenital folds become the labia minora – Labioscrotal folds
    [Show full text]
  • Chapter 24 Primary Sex Organs = Gonads Produce Gametes Secrete Hormones That Control Reproduction Secondary Sex Organs = Accessory Structures
    Anatomy Lecture Notes Chapter 24 primary sex organs = gonads produce gametes secrete hormones that control reproduction secondary sex organs = accessory structures Development and Differentiation A. gonads develop from mesoderm starting at week 5 gonadal ridges medial to kidneys germ cells migrate to gonadal ridges from yolk sac at week 7, if an XY embryo secretes SRY protein, the gonadal ridges begin developing into testes with seminiferous tubules the testes secrete androgens, which cause the mesonephric ducts to develop the testes secrete a hormone that causes the paramesonephric ducts to regress by week 8, in any fetus (XX or XY), if SRY protein has not been produced, the gondal ridges begin to develop into ovaries with ovarian follicles the lack of androgens causes the paramesonephric ducts to develop and the mesonephric ducts to regress B. accessory organs develop from embryonic duct systems mesonephric ducts / Wolffian ducts eventually become male accessory organs: epididymis, ductus deferens, ejaculatory duct paramesonephric ducts / Mullerian ducts eventually become female accessory organs: oviducts, uterus, superior vagina C. external genitalia are indeterminate until week 8 male female genital tubercle penis (glans, corpora cavernosa, clitoris (glans, corpora corpus spongiosum) cavernosa), vestibular bulb) urethral folds fuse to form penile urethra labia minora labioscrotal swellings fuse to form scrotum labia majora urogenital sinus urinary bladder, urethra, prostate, urinary bladder, urethra, seminal vesicles, bulbourethral inferior vagina, vestibular glands glands Strong/Fall 2008 Anatomy Lecture Notes Chapter 24 Male A. gonads = testes (singular = testis) located in scrotum 1. outer coverings a. tunica vaginalis =double layer of serous membrane that partially surrounds each testis; (figure 24.29) b.
    [Show full text]
  • AAGL Practice Report: Practice Guidelines for Management of Intrauterine Synechiae
    Special Article AAGL Practice Report: Practice Guidelines for Management of Intrauterine Synechiae AAGL ADVANCING MINIMALLY INVASIVE GYNECOLOGY WORLDWIDE Background The search was not restricted to English language literature; committee members fluent in languages other than English re- Intrauterine adhesions (IUAs) have been recognized as viewed relevant articles and provided the committee with rel- a cause of secondary amenorrhea since the end of the 19th ative information translated into English. Because of the century [1], and in the mid-20th century, Asherman further paucity of data in this area, all published works were included described the eponymous condition occurring after preg- for the electronic database searches, and relevant articles not nancy [2]. The terms ‘‘Asherman syndrome’’ and IUAs are available in electronic sources (e.g., published before the be- often used interchangeably, although the syndrome requires ginning of electronic database commencement) were cross- the constellation of signs and symptoms (in this case, pain, referenced from hand-searched bibliographies and included menstrual disturbance, and subfertility in any combination) in the literature review. When necessary, authors were con- and the presence of IUAs [2]. The presence of IUAs in the tacted directly for clarification of points published. absence of symptoms may be best referred to as asymptom- atic IUAs or synechiae. Diagnosis Identification and Assessment of Evidence In women with suspected IUAs, physical examination usually fails to reveal abnormalities [3,4]. Blind transcervical This AAGL Practice Guideline was produced after elec- sounding of the uterus may reveal cervical obstruction at or tronic resources including Medline, PubMed, CINAHL, the near the level of the internal os [3].
    [Show full text]
  • Airway Obstruction After Biopsy by Cervical Mediastinoscopy in a Patient with a Mediastinal Mass -A Case Report
    Korean J Anesthesiol 2012 July 63(1): 65-67 Case Report http://dx.doi.org/10.4097/kjae.2012.63.1.65 Airway obstruction after biopsy by cervical mediastinoscopy in a patient with a mediastinal mass -A case report- Yong-Cheol Lee2, Sang-Jin Park1, and In-seong Kim1 Department of Anesthesiology and Pain Medicine, 1College of Medicine, Yeungnam University, 2School of Medicine, Keimyung University, Daegu, Korea Biopsy, using mediastinoscopy is commonly employed for accurate histologic diagnosis of a mediastinal mass. However, since the mass is not removed during the procedure, it may cause compression of vital structures such as major airways, the heart, the pulmonary artery, and the superior vena cava after surgery. We observed a case of a 66-year-old man with a mediastinal mass that caused severe airway obstruction during recovery from anesthesia following mediastinoscopic biopsy, probably caused by upper airway edema which seemed to originate from compression of the superior vena cava. Therefore, we suggest that unexpected airway obstruction in a patient with a mediastinal mass can be due to superior vena cava compression. (Korean J Anesthesiol 2012; 63: 65-67) Key Words: Airway obstruction, Mediastinoscopy, Superior vena cava. Biopsies, using mediastinoscopy are commonly utilized Case Report to decide on the treatment of mediastinal masses. However, since the mass is not removed during the biopsy, it may cause A 66-year-old man visited the hospital with a one month compression of vital structures after the procedure [1]. The history of chest discomfort and sporadic swelling in the face superior vena cava has an especially low intravascular pressure and arms in the morning.
    [Show full text]
  • Colorectal Cancer Screening
    CLINICAL MEDICAL POLICY Policy Name: Colorectal Cancer Screening Policy Number: MP-059-MD-PA Responsible Department(s): Medical Management Provider Notice Date: 03/19/2021 Issue Date: 03/19/2021 Effective Date: 04/19/2021 Next Annual Review: 02/2022 Revision Date: 02/17/2021 Products: Gateway Health℠ Medicaid Application: All participating hospitals and providers Page Number(s): 1 of 10 DISCLAIMER Gateway Health℠ (Gateway) medical policy is intended to serve only as a general reference resource regarding coverage for the services described. This policy does not constitute medical advice and is not intended to govern or otherwise influence medical decisions. POLICY STATEMENT Gateway Health℠ may provide coverage under the medical-surgical benefits of the Company’s Medicaid products for medically necessary colorectal cancer screening procedures. This policy is designed to address medical necessity guidelines that are appropriate for the majority of individuals with a particular disease, illness or condition. Each person’s unique clinical circumstances warrant individual consideration, based upon review of applicable medical records. (Current applicable Pennsylvania HealthChoices Agreement Section V. Program Requirements, B. Prior Authorization of Services, 1. General Prior Authorization Requirements.) Policy No. MP-059-MD-PA Page 1 of 10 DEFINITIONS Average-Risk Population – Patient population defined as having no personal history of adenomatous polyps, colorectal cancer, or inflammatory bowel disease (Crohn’s disease and Ulcerative Colitis); no family history of colorectal cancer or adenomatous polyps, familial adenomatous polyposis, or hereditary nonpolyposis colorectal cancer. High-Risk Population – Patient population defined as having a first-degree relative (sibling, parent, or child) who has had colorectal cancer or adenomatous polyps; OR family history of familial adenomatous polyposis; OR family history of hereditary non-polyposis colorectal cancer; OR family history of MYH- associated polyposis in siblings; OR diagnosis of Cowden syndrome.
    [Show full text]
  • The Importance of Orofacial Myofunctional Therapy Before and After CO2 Laser Frenectomy in Achieving Optimal Orofacial Function
    LASERfocus The Importance of Orofacial Myofunctional Therapy Before and After CO2 Laser Frenectomy in Achieving Optimal Orofacial Function by Karen M. Wuertz, DDS, ABCDSM, DABLS, FOM, and Brooke Pettus, RDH, BSDH, COMS Frenectomy Methods ing, speaking, and breathing patterns may be Frenotomies performed with a scalpel or scissors can be accompanied by caused by incorrect oral posture and oral re- significant bleeding, obscuring the surgical field making it difficult to ensure strictions. Therefore, in the authors’ opinion, if the restriction has been completely removed. Because of the increased risk the removal of oral restrictions is necessary to of early primary closure of the site, postoperative active wound care is es- attain optimal orofacial function, and must be sential to reduce the risk of potential scarring. To properly restore and main- combined with regular pre- and post-frenecto- tain optimum function, active wound care should be implemented as soon my orofacial myofunctional therapy (OMT).1,4 as possible. However, if sutures are placed, the active wound care may be OMT helps re-educate the tongue and orofa- delayed so as not to cause early tearing of tissue. Due to the contact nature of cial muscles during movement and at rest to conventional procedure, there is a certain potential for infection; in addition, create new neuromuscular patterns for proper higher levels of postoperative pain and discomfort have been reported.1,2 Elec- oral function, including chewing, swallowing, trocautery and a hot glass tip of dental diodes may leave a fairly substantial speaking, and breathing.5,6 Camacho et al.7 zone of thermal tissue change3 and may result in delayed healing.
    [Show full text]
  • Fearful Symmetries: Essays and Testimonies Around Excision and Circumcision. Rodopi
    Fearful Symmetries Matatu Journal for African Culture and Society ————————————]^——————————— EDITORIAL BOARD Gordon Collier Christine Matzke Frank Schulze–Engler Geoffrey V. Davis Aderemi Raji–Oyelade Chantal Zabus †Ezenwa–Ohaeto TECHNICAL AND CARIBBEAN EDITOR Gordon Collier ———————————— ]^ ——————————— BOARD OF ADVISORS Anne V. Adams (Ithaca NY) Jürgen Martini (Magdeburg, Germany) Eckhard Breitinger (Bayreuth, Germany) Henning Melber (Windhoek, Namibia) Margaret J. Daymond (Durban, South Africa) Amadou Booker Sadji (Dakar, Senegal) Anne Fuchs (Nice, France) Reinhard Sander (San Juan, Puerto Rico) James Gibbs (Bristol, England) John A. Stotesbury (Joensuu, Finland) Johan U. Jacobs (Durban, South Africa) Peter O. Stummer (Munich, Germany) Jürgen Jansen (Aachen, Germany) Ahmed Yerma (Lagos, Nigeria)i — Founding Editor: Holger G. Ehling — ]^ Matatu is a journal on African and African diaspora literatures and societies dedicated to interdisciplinary dialogue between literary and cultural studies, historiography, the social sciences and cultural anthropology. ]^ Matatu is animated by a lively interest in African culture and literature (including the Afro- Caribbean) that moves beyond worn-out clichés of ‘cultural authenticity’ and ‘national liberation’ towards critical exploration of African modernities. The East African public transport vehicle from which Matatu takes its name is both a component and a symbol of these modernities: based on ‘Western’ (these days usually Japanese) technology, it is a vigorously African institution; it is usually
    [Show full text]
  • Update in Anaesthesia
    Update in Anaesthesia Pulmonary Function Tests and Assessment for Lung Resection David Portch*, Bruce McCormick *Correspondence Email: [email protected] INTRODUCTION Summary respectively. There are 2400 lobectomies and 500 The aim of this article is to describe the tests available This article describes the for the assessment of patients presenting for lung pneumonectomies performed in the UK each year, steps taken to evaluate resection. The individual tests are explained and we with in-hospital mortality 2-4% for lobectomy and patients’ fitness for lung 4 describe how patients may progress through a series of 6-8% for pneumonectomy. resection surgery. Examples tests to identify those amenable to lung resection. Lung resection is most frequently performed to treat are used to demonstrate interpretation of these tests. Pulmonary function testing is a vital part of the non-small cell lung cancer. This major surgery places It is vital to use these tests in assessment process for thoracic surgery. However, large metabolic demands on patients, increasing conjunction with a thorough for other types of surgery there is no evidence postoperative oxygen consumption by up to 50%. history and examination that spirometry is more effective than history and Patients presenting for lung resection are often high in order to achieve an examination in predicting postoperative pulmonary risk due to a combination of their age (median age accurate assessment of each complications in patients with known chronic lung is 70 years)5 and co-morbidities. Since non-surgical patient’s level of function. conditions. Furthermore specific spirometric values mortality approaches 100%, a thorough assessment of Much of this assessment (e.g.
    [Show full text]
  • Aguide to Evidence-Based Practices
    A GUIDE TO EVIDENCE-BASED PRACTICES for INDIVIDUALS WITH DEVELOPMENTAL DISABILITIES This report was produced with the support of the Saginaw County Community Mental Health Authority May 2009 Compiled by Barbara Glassheim This document may not be reproduced or distributed without the express permission of SCCMHA A GUIDE TO EVIDENCE-BASED PRACTICES FOR INDIVIDUALS WITH DEVELOPMENTAL DISABILITIES V. 1.0 TABLE OF CONTENTS FORWARD ............................................................................................................... 1 EXECUTIVE SUMMARY ............................................................................................. 2 INTRODUCTION ....................................................................................................... 4 AN OVERVIEW OF EVIDENCE-BASED PRACTICE CONCEPTS ........................................... 7 CULTURAL CONSIDERATIONS ................................................................................. 10 MALTREATMENT ................................................................................................ 10 WOMEN ............................................................................................................. 11 OLDER ADULTS .................................................................................................. 11 ETHNIC GROUPS ................................................................................................ 12 DEAF CULTURE .................................................................................................. 13 EMPOWERMENT
    [Show full text]
  • 114.3 Cmr: Division of Health Care Finance and Policy Ambulatory Care
    114.3 CMR: DIVISION OF HEALTH CARE FINANCE AND POLICY AMBULATORY CARE 114.3 CMR 40.00: RATES FOR SERVICES UNDER M.G.L. c. 152, WORKERS’ COMPENSATION ACT Section 40.01: General Provisions 40.02: General Definitions 40.03: Service and Rate Coverage Provisions 40.04: Provisions Affecting Eligible Providers 40.05: Policies for Individual Service Types 40.06: Fees 40.07: Appendices 40.08: Severability 40.01: General Provisions (1) Scope, Purpose and Effective Date. 114.3 CMR 40.00 governs the payment rates effective April 1, 2009 for purchasers of health care services under M.G.L. c. 152, the Workers’ Compensation Act. Payment rates for services provided by hospitals are set forth in 114.1 CMR 41.00. Program policies relating to medical necessity and clinical appropriateness are determined pursuant to M.G.L. c. 152 and 452 CMR 6.00. (2) Coverage. The payment rates set forth in 114.3 CMR 40.06 are full payment for services provided under M.G.L. c. 152, § 13, including any related administrative or overhead costs. The insurer, employer and health care service provider may agree upon a different payment rate for any service set forth in the fee schedule in 114.3 CMR 40.00. No employee may be held liable for the payment for health care services determined compensable under M.G.L. c. 152, § 13. (3) Administrative Bulletins. The Division may issue administrative bulletins to clarify substantive provisions of 114.3 CMR 40.00, or to publish procedure code updates and corrections. For coding updates and correction, the bulletin will list: (a) new code numbers for existing codes, with the corresponding cross references between existing and new codes numbers; (b) deleted codes for which there are no corresponding new codes; and (c) codes for entirely new services that require pricing.
    [Show full text]
  • Comparison of Curettage and Hysteroscopy Plus Curettage After Uterine Arterial Embolization in the Treatment of Cesarean Scar Pregnancy
    Comparison of Curettage and Hysteroscopy Plus Curettage After Uterine Arterial Embolization in the Treatment of Cesarean Scar Pregnancy Lili Cao Women's Hospital, Zhejiang University School of Medicine Zhida Qian Women's Hospital, Zhejiang University School of Medicine Lili Huang ( [email protected] ) Women's Hospital, Zhejiang University School of Medicine https://orcid.org/0000-0002-5919-3172 Research article Keywords: Cesarean scar pregnancy, Hysteroscopy, Curettage, Uterine artery embolization Posted Date: July 2nd, 2020 DOI: https://doi.org/10.21203/rs.3.rs-39244/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/11 Abstract Background: Caesarean scar pregnancy (CSP) stands for the advanced stage severe complication secondary to cesarean section, and its incidence shows an increasing trend recently. However, no consensus has been reached about the optimal CSP treatment. Methods: The childbearing CSP patients with a cesarean section history were evaluated by ultrasonography, with a gestational age of less than 10 weeks. 34 patients receiving dilation and curettage (D&C) and uterine artery embolization (UAE) were enrolled into the D&C group, while 46 undergoing hysteroscopy (H/S) and D&C after UAE were enrolled into the H/S+D&C group. Results: Differences in success rate and decrease in the β-hCG level in serum on the second day of surgery were not signicant between D&C and H/S+D&C groups (P>0.05). Also, differences in side effect rate, intraoperative blood loss amount, postoperative bleeding time, and total length of stay were not signicant between both groups (P>0.05).
    [Show full text]